Johansen S
Eur J Clin Pharmacol. 1985;28(1):23-8. doi: 10.1007/BF00635703.
In a double-blind, randomized study, the long-term effects of timolol and placebo on FEV1, PEFR, FVC, VC, respiratory rate and heart rate were compared in 32 patients surviving acute myocardial infarction, 17 on timolol and 15 on placebo. The patients were assessed before and after 1, 3 and 6 months of medication, and then every 6 months for up to 2 years; the mean observation period was 17.4 months. Timolol decreased FEV1 significantly (9-17%) throughout the study. PEFR and FVC fell by 4-13% and 9-11%, respectively, on timolol; the reductions were significant at 3, 6 and 24 months, and at 1, 3 and 6 months, respectively. VC showed only small changes and respiratory rate did not change. In only one patient were the changes in pulmonary function of clinical relevance. Thus, significant, persisting airways dysfunction was induced by long-term beta-adrenergic blockade in patients surviving myocardial infarction.
在一项双盲随机研究中，比较了噻吗洛尔和安慰剂对32例急性心肌梗死存活患者的第一秒用力呼气容积（FEV1）、呼气峰流速（PEFR）、用力肺活量（FVC）、肺活量（VC）、呼吸频率和心率的长期影响，其中17例服用噻吗洛尔，15例服用安慰剂。在用药1、3和6个月之前及之后对患者进行评估，然后每6个月评估一次，最长持续2年；平均观察期为17.4个月。在整个研究过程中，噻吗洛尔使FEV1显著降低（9%-17%）。服用噻吗洛尔时，PEFR和FVC分别下降了4%-13%和9%-11%；在3、6和24个月时以及1、3和6个月时，下降具有显著性。VC仅有微小变化，呼吸频率未改变。只有1例患者的肺功能变化具有临床相关性。因此，心肌梗死存活患者长期使用β-肾上腺素能阻滞剂会导致显著且持续的气道功能障碍。
